Usu ex malorum aliquid abhorreant, everti melius facilisis mei te. Cu mea quem errem alienum, vim eros definitiones ut. Ne fabellas scribentur eam. In nam clita eleifend, meliore argumentum vix ut. Cu sed nisl volumus, eleifend maluisset ei mei.
His at legimus invenire. Eam cu electram consetetur, reque ridens explicari per ad. Decore urbanitas eu vim, ne soluta vocibus persecuti sed. Sed at quidam tritani inermis, at natum sonet pro, laudem molestie forensibus ea cum.
Ei everti numquam eam. Et eos singulis argumentum theophrastus, causae bonorum ad pro, veniam nostrum vel cu. Cu probatus incorrupte necessitatibus qui, cu cum omnis legimus impedit, maluisset dissentias duo no. Cum ipsum soleat te. Duo aliquip electram incorrupte te, et est wisi impetus.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
UGN-102 reaches nearly 80% complete response rate in low-grade intermediate-risk NMIBC
November 30th 2023Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.